Download presentation
Presentation is loading. Please wait.
Published byMarjory Jane Bruce Modified over 8 years ago
1
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up Christian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, Jin-Seok Ahn, Bohuslav Melichar, Shin-Cheh Chen, Sung-Bae Kim, Mikhail Lichinitser, Elżbieta Starosławska, Georg Kunz, Silvia Falcon, Shou-Tung Chen, Aulde Crepelle-Fléchais, Dominik Heinzmann, Mona Shing, Xavier Pivot European Journal of Cancer Volume 62, Pages 62-75 (July 2016) DOI: 10.1016/j.ejca.2016.03.087 Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
2
Fig. 1 European Journal of Cancer 2016 62, 62-75DOI: (10.1016/j.ejca.2016.03.087) Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
3
Fig. 2 European Journal of Cancer 2016 62, 62-75DOI: (10.1016/j.ejca.2016.03.087) Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
4
Fig. 3 European Journal of Cancer 2016 62, 62-75DOI: (10.1016/j.ejca.2016.03.087) Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
5
Fig. 4 European Journal of Cancer 2016 62, 62-75DOI: (10.1016/j.ejca.2016.03.087) Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
6
Fig. 5 European Journal of Cancer 2016 62, 62-75DOI: (10.1016/j.ejca.2016.03.087) Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
7
Fig. 6 European Journal of Cancer 2016 62, 62-75DOI: (10.1016/j.ejca.2016.03.087) Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
8
Fig. 6 European Journal of Cancer 2016 62, 62-75DOI: (10.1016/j.ejca.2016.03.087) Copyright © 2016 The Author(s) Terms and Conditions Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.